Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a deal with privately held Mammoth Biosciences to research, develop and commercialize Crispr-based gene-editing therapies targeting multiple diseases.
The collaboration will expand Regeneron’s genetic medicines presence with more gene editing programs, and is designed to combine Mammoth’s platform with Regeneron’s effort to develop adeno-associated viral vectors (AAVs) that use antibody-based targeting to enhance delivery of genetic medicine payloads to specific tissues and cell types.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze